Affiliation:
1. Friends for International TB Relief
2. Stop TB Partnership
3. International Centre for Diarrhoeal Disease Research
4. Janna Health Foundation
5. Centre for Infectious Disease Research in Zambia
6. Liverpool School of Tropical Medicine
Abstract
Abstract
Background
In 2022, fewer than half of persons with tuberculosis (TB) have access to molecular diagnostic tests for TB due to their high costs. Studies have found that computer-aided detection using artificial intelligence (AI) for chest X-ray (CXR) and sputum specimen pooling can each reduce testing costs. We modeled the combination of both strategies to estimate potential savings in consumables that could be used to expand access to molecular diagnostics.
Methods
We obtained Xpert testing and positivity data segmented into deciles by AI probability scores for TB from community- and healthcare facility-based active case finding conducted in Bangladesh, Nigeria, Viet Nam and Zambia. AI scores in the model were based on CAD4TB version 7 (Zambia) and qXR (all other countries). We modeled four ordinal screening and testing approaches involving computer-aided CXR to indicate individual and pooled testing. Setting a false negative rate of 5%, for each approach we calculated additional and cumulative savings over the baseline of universal Xpert testing as well as the theoretical expansion in diagnostic coverage.
Results
In each country, the optimal screening and testing approach was to use AI to rule out testing in deciles with low AI scores and guide pooled and individual testing in persons with moderate and high AI scores, respectively. This approach yielded cumulative savings in Xpert tests over baseline ranging from 50.8% in Zambia to 57.5% in Nigeria and 61.5% in Bangladesh and Viet Nam. Using these savings, diagnostic coverage theoretically could be expanded by 34–160% across the different approaches and countries.
Conclusions
Using a combination of AI and CXR to inform different pooling strategies may optimize TB diagnostic test use, and could extend molecular tests to more people who need them. The optimal AI thresholds and pooled testing strategy varied across countries, which suggests that bespoke screening and testing approaches may be needed for differing populations and settings.
Publisher
Research Square Platform LLC
Reference42 articles.
1. GeneXpert—A Game-Changer for Tuberculosis Control?;Evans CA;PLoS Med,2011
2. Rapid Diagnosis of Mycobacterium tuberculosis with Truenat MTB: A Near-Care Approach;Nikam C;PLoS One,2013
3. Branigan D. Tuberculosis Diagnostics Pipeline Report » 2023. 2023.
4. World Health Organization. Global Tuberculosis Report 2023. Geneva, Switzerland; 2023.
5. World Health Organization. WHO standard: universal access to rapid tuberculosis diagnostics. Geneva, Switzerland: World Health Organization; 2023.